Author:
Song Zhengbo,Liu Tianchi,Shi Lei,Yu Zongyang,Shen Qing,Xu Mengdi,Huang Zhangzhou,Cai Zhijian,Wang Wenxian,Xu Chunwei,Sun Jingjing,Chen Ming
Funder
National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Subject
Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine
Reference39 articles.
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. Wiley. 2020;70(1):7–30 https://pubmed.ncbi.nlm.nih.gov/31912902/. Accessed 10 July 2020.
2. Blackhall FH, Peters S, Bubendorf L, et al. Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape project. J Clin Oncol. American Society of Clinical Oncology. 2014;32(25):2780–7.
3. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–6 http://www.ncbi.nlm.nih.gov/pubmed/17625570. Accessed 11 Apr 2020.
4. Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non–small-cell lung cancer. N Engl J Med. Massachussetts Medical Society; 2017;377(9):829–838. http://www.nejm.org/doi/10.1056/NEJMoa1704795. Accessed 11 Apr 2020.
5. Solomon BJ, Kim DW, Wu YL, et al. Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in alk-mutation-positive non–small-cell lung cancer. J Clin Oncol. American Society of Clinical Oncology. 2018;36(22):2251–8.
Cited by
35 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献